ethyl ((3,4,5-trihydroxy-6-((4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1H-pyrazol-3-yl)oxy)tetrahydro-2H-pyran-2-yl)methyl) carbonate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl ((3,4,5-trihydroxy-6-((4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1H-pyrazol-3-yl)oxy)tetrahydro-2H-pyran-2-yl)methyl) carbonate
• 英文别名: ethyl [3,4,5-trihydroxy-6-[5-methyl-1-propan-2-yl-4-[(4-propan-2-yloxyphenyl)methyl]pyrazol-3-yl]oxyoxan-2-yl]methyl carbonate
• 化学式: C₂₆H₃₈N₂O₉
• 分子量: 522.6
• InChiKey: UAOCLDQAQNNEAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  37
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  142
• 氢给体数：
  3
• 氢受体数：
  10

文献信息

• Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
  申请人：Green James Trinca

  公开号：US10940159B2

  公开（公告）日：2021-03-09

  A combination immediate/delayed release delivery system for compounds which have short half-life's, such as the antidiabetic remogliflozin etabonate, is provided which provides a dosage form that has two distinct phases of release, a formulation that promotes immediate release of the compound upon ingestion and another formulation which delays the release of the compound so that a dosing regimen of remogliflozin etabonate, once daily, may be achieved while providing effective control of plasma glucose and minimizing the nighttime exposure of this compound. The delivery system includes, but is not limited to, a combination of enteric coating of an immediate release formulation such that a delay in release is provided. Methods for forming the so-described immediate/delayed release delivery system and using such delivery system for treating diabetes are also provided.

  本发明为半衰期较短的化合物（如抗糖尿病药物雷莫格列嗪依他朋酸酯）提供了一种速释/缓释组合给药系统，该系统提供了一种具有两个不同释放阶段的剂型，一种剂型可促进化合物在摄入后立即释放，另一种剂型可延迟化合物的释放，从而可实现雷莫格列嗪依他朋酸酯每日一次的给药方案，同时有效控制血浆葡萄糖，并最大限度地减少该化合物的夜间暴露。该给药系统包括但不限于速释制剂的肠溶包衣组合，从而提供延迟释放。此外，还提供了形成上述速释/缓释给药系统和使用这种给药系统治疗糖尿病的方法。
• ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER
  申请人：IC-MedTech Corp.

  公开号：US20210283100A1

  公开（公告）日：2021-09-16

  Provided herein is a method of treating, preventing, or alleviating one or more symptoms of cancer in a subject, comprising administering to the subject a therapeutically effective amount of: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) a sodium glucose cotransporter inhibitor, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.